Unleashing the potential of stem cells for targeted antimicrobial treatment
Gene & Protein in Disease · 2023
DOI: 10.36922/gpd.1230 ↗Kurz gefasst
Fachartikel in der Zeitschrift Gene & Protein in Disease, 2023. Verfasst von Ali Yetgin. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Infectious diseases continue to pose a serious threat to human health as a result of the spread of antibiotic resistance, underscoring the urgent need for new and focused therapeutic approaches. Due to their regenerative and immunomodulatory capabilities, stem cells have emerged as a potential source for the development of antimicrobial therapies. This paper reviews the potential of stem cells as a targeted strategy for combating infections, focusing on their ability to differentiate into specific cell types that can directly target and eliminate microorganisms, as well as their capacity to modulate the immune response and enhance host defenses. The article discusses the challenges and opportunities associated with the clinical implementation of antimicrobial therapies derived from stem cells. Among these obstacles are the need for uniform protocols for cell isolation, expansion, and delivery, as well as the significance of rigorous evaluations of safety and efficacy. Despite that, the application of stem cells as a targeted antimicrobial approach holds significant potential for the development of effective and enduring therapeutic interventions for infectious diseases.
Zitieren
APA
Yetgin, A. (2023). Unleashing the potential of stem cells for targeted antimicrobial treatment. Gene & Protein in Disease. https://doi.org/10.36922/gpd.1230
Vancouver
Yetgin A. Unleashing the potential of stem cells for targeted antimicrobial treatment. Gene & Protein in Disease. 2023. doi:10.36922/gpd.1230
BibTeX
@article{Yetgin2023,
author = {Yetgin, Ali},
title = {Unleashing the potential of stem cells for targeted antimicrobial treatment},
journal = {Gene & Protein in Disease},
year = {2023},
doi = {10.36922/gpd.1230}
}
EUVIMED